Brief: Diamedica Receives FDA Feedback On Dm199 Preeclampsia Nonclinical Program
16/06/2026 13:58
BRIEF-Diamedica Receives FDA Feedback On Dm199 Preeclampsia Nonclinical Program June 16 (Reuters) - DiaMedica Therapeutics Inc DMAC.O:
DIAMEDICA RECEIVES FDA FEEDBACK ON DM199 PREECLAMPSIA NONCLINICAL PROGRAM
DIAMEDICA THERAPEUTICS - PRIOR RAT TOXICITY STUDY MAY SUPPORT U.S. IND IF DM199 EXPOSURE AND ACTIVITY SHOWN
DIAMEDICA THERAPEUTICS - INITIATES RAT PHARMACOKINETIC AND ACTIVITY STUDY OF DM199
DIAMEDICA THERAPEUTICS - TO SUBMIT RAT PK STUDY DATA TO FDA UPON COMPLETION
Source text: ID:nBw9y1Q5Pa
Further company coverage: DMAC.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on DiaMedica Therapeutics
See all newsBrief: Diamedica Therapeutics Announces Enrollment Of 200Th Patient In Remedy2 Phase 2/3 Acute Ischemic Stroke Trial
DiaMedica Q2 net loss widen less than expected
DiaMedica Therapeutics Inc expected to post a loss of 20 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Qualcomm, Robinhood
Brief: Diamedica Receives FDA Feedback On Dm199 Preeclampsia Nonclinical Program